Kim JW - Search Results

1

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Among authors: kim jw. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25. Future Oncol. 2023. PMID: 37746835 Free article. Review.

2

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY. Kim HP, et al. Among authors: kim ty, kim jw. PLoS One. 2009 Jun 16;4(6):e5933. doi: 10.1371/journal.pone.0005933. PLoS One. 2009. PMID: 19529774 Free PMC article.

3

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Seog Heo D, Bang YJ. Kim SJ, et al. Among authors: kim dw, kim ty, kim jw. BMC Cancer. 2010 Aug 23;10:448. doi: 10.1186/1471-2407-10-448. BMC Cancer. 2010. PMID: 20731845 Free PMC article.

4

Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.

Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Kim JW, et al. Among authors: kim dw, kim ty, kim sj. Support Care Cancer. 2012 Feb;20(2):395-403. doi: 10.1007/s00520-011-1126-8. Epub 2011 Mar 11. Support Care Cancer. 2012. PMID: 21390568 Clinical Trial.

5

Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).

Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ. Kim SJ, et al. Among authors: kim dw, kim ty, kim jw. Am J Clin Oncol. 2012 Dec;35(6):549-56. doi: 10.1097/COC.0b013e31821dee0f. Am J Clin Oncol. 2012. PMID: 21659833

6

The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.

Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH, Bang YJ. Kim JW, et al. Among authors: kim wh, kim ma, kim ty, kim m. Anticancer Res. 2012 Apr;32(4):1547-53. Anticancer Res. 2012. PMID: 22493400

7

Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.

Kang EJ, Im SA, Oh DY, Han SW, Kim JS, Choi IS, Kim JW, Kim YJ, Kim JH, Kim TY, Lee JS, Bang YJ, Lee KW. Kang EJ, et al. Among authors: kim yj, kim ty, kim js, kim jw, kim jh. Gastric Cancer. 2013 Oct;16(4):581-9. doi: 10.1007/s10120-012-0227-5. Epub 2012 Dec 25. Gastric Cancer. 2013. PMID: 23266882

8

Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.

Kim JW, Im SA, Kim MA, Cho HJ, Lee DW, Lee KH, Kim TY, Han SW, Oh DY, Lee HJ, Kim TY, Yang HK, Kim WH, Bang YJ. Kim JW, et al. Among authors: kim wh, kim ma, kim ty. Int J Cancer. 2014 Jan 1;134(1):72-80. doi: 10.1002/ijc.28245. Epub 2013 Sep 17. Int J Cancer. 2014. PMID: 23649938 Free article.

9

Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.

Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Kim WH, Bang YJ, Oh DY. Ock CY, et al. Among authors: kim wh, kim ty, kim js, kim jw. Clin Cancer Res. 2015 Jun 1;21(11):2520-9. doi: 10.1158/1078-0432.CCR-14-2659. Epub 2015 Feb 23. Clin Cancer Res. 2015. PMID: 25712681

10

A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.

Kim JW, Choi IS, Kim YJ, Lee KH, Lee KW, Kim TY, Han SW, Kim JH, Kim TY, Lee JS, Bang YJ, Im SA, Oh DY. Kim JW, et al. Among authors: kim yj, kim ty, kim jh. Cancer Chemother Pharmacol. 2015 Jun;75(6):1175-82. doi: 10.1007/s00280-015-2732-9. Epub 2015 Apr 10. Cancer Chemother Pharmacol. 2015. PMID: 25860347 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,714 results

Search Page